Personalized medicine for allergy treatment: Allergen immunotherapy still a unique and unmatched model.
allergen immunotherapy
molecular diagnosis
omics
personalized medicine
treatable traits
Journal
Allergy
ISSN: 1398-9995
Titre abrégé: Allergy
Pays: Denmark
ID NLM: 7804028
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
revised:
18
08
2020
received:
09
06
2020
accepted:
20
08
2020
pubmed:
2
9
2020
medline:
15
5
2021
entrez:
2
9
2020
Statut:
ppublish
Résumé
The introduction of personalized medicine (PM) has been a milestone in the history of medical therapy, because it has revolutionized the previous approach of treating the disease with that of treating the patient. It is known today that diseases can occur in different genetic variants, making specific treatments of proven efficacy necessary for a given endotype. Allergic diseases are particularly suitable for PM, because they meet the therapeutic success requirements, including a known molecular mechanism of the disease, a diagnostic tool for such disease, and a treatment blocking the mechanism. The stakes of PM in allergic patients are molecular diagnostics, to detect specific IgE to single-allergen molecules and to distinguish the causative molecules from those merely cross-reactive, pursuit of patient's treatable traits addressing genetic, phenotypic, and psychosocial features, and omics, such as proteomics, epi-genomics, metabolomics, and breathomics, to forecast patient's responsiveness to therapies, to detect biomarker and mediators, and to verify the disease control. This new approach has already improved the precision of allergy diagnosis and is likely to significantly increase, through the higher performance achieved with the personalized treatment, the effectiveness of allergen immunotherapy by enhancing its already known and unique characteristics of treatment that acts on the causes.
Substances chimiques
Allergens
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1041-1052Informations de copyright
© 2020 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
Références
Jones AW. Early drug discovery and the rise of pharmaceutical chemistry. Drug Test Anal. 2011;3(6):337-344.
Mahner M, Kary M. What exactly are genomes, genotypes and phenotypes? And what about phenomes? J Theoretical Biol. 1997;186:55-63.
Febbo PG, Ginsburg GS. Personalized diagnostic and therapeutic strategies in oncology. Per Med. 2005;2(2):97-110.
Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372(9):793-795.
Busse WW. Biological treatments for severe asthma: a major advance in asthma care. Allergol Int. 2019;68(2):158-166.
Frew AJ. Hundred years of allergen immunotherapy. Clin Exp Allergy. 2011;41(9):1221-1225.
Canonica GW, Bachert C, Hellings P, et al. Allergen immunotherapy (AIT): a prototype of precision medicine. World Allergy Organ J. 2015;8(1):312015.
Roberts G, Pfaar O, Akdis CA, et al. EAACI guidelines on allergen immunotherapy: allergic rhinoconjunctivitis. Allergy. 2018;73(4):765-798.
Demoly P, Makatsori M, Casale TB, Calderon MA. The potential role of allergen immunotherapy in stepping down asthma treatment. J Allergy Clin Immunol Pract. 2017;5(3):640-648.
Adkinson NF Jr, Eggleston PA, Eney D, et al. A controlled trial of immunotherapy for asthma in allergic children. N Engl J Med. 1997;336(5):324-331.
Kaul S, May S, Lüttkopf D, Vieths S. Regulatory environment for allergen-specific immunotherapy. Allergy. 2011;66(6):753-764.
Devillier P, Dreyfus JF, Demoly P, Calderón MA. A meta-analysis of sublingual allergen immunotherapy and pharmacotherapy in pollen-induced seasonal allergic rhinoconjunctivitis. BMC Med. 2014;12:71.
Larenas-Linnemann D, Cox LS. Immunotherapy and allergy diagnostics Committee of the American Academy of Allergy, Asthma and Immunology European allergen extract units and potency: review of available information. Ann Allergy Asthma Immunol. 2008;100(2):137-145.
Larenas-Linnemann D, Esch R, Plunkett G, et al. Maintenance dosing for sublingual immunotherapy by prominent European allergen manufacturers expressed in bioequivalent allergy units. Ann Allergy Asthma Immunol. 2011;107(5):448-458.
Valenta R, Lidholm J, Niederberger V, Hayek B, Kraft D, Grönlund H. The recombinant allergen-based concept of component-resolved diagnostics and immunotherapy (CRD and CRIT). Clin Exp Allergy. 1999;29(7):896-904.
Melioli G, Savi E, Crivellaro MA, Passalacqua G. Potential of molecular based diagnostics and its impact on allergen immunotherapy. Asthma Res Pract. 2016;2:9.
Kespohl S, Raulf M. Mould allergens: where do we stand with molecular allergy diagnostics?: part 13 of the series molecular allergology. Allergo J Int. 2014;23(4):120-125.
Steering Committee Authors and Review Panel Members. A WAO - ARIA - GA2LEN consensus document on molecular-based allergy diagnosis (PAMD@): update 2020. World Allergy Organ J. 2020;13(2):10009.
Pomes A, Davies JM, Gadermaier G, et al. WHO/IUIS allergen nomenclature: providing a common language. Mol Immunol. 2018;100:3-13.
van Hage M, Hamsten C, Valenta R. ImmunoCAP assays: pros and cons in allergology. J Allergy Clin Immunol. 2017;140:974-977.
Garib V, Rigler E, Gastager F, et al. Determination of IgE and IgG reactivity to more than 170 allergen molecules in paper dried blood spots. J Allergy Clin Immunol. 2019;143:437-440.
Jakob T, Forstenlechner P, Matricardi P, Kleine-Tebbe J. Molecular allergy diagnostics using multiplex assays: methodological and practical considerations for use in research and clinical routine: Part 21 of the Series Molecular Allergology. Allergo J Int. 2015;24:320-332.
van Hage M, Schmid-Grendelmeier P, Skevaki C, et al. Performance evaluation of ImmunoCAP® ISAC 112: a multi-site study. Clin Chem Lab Med. 2017;55(4):571-577.
Di Fraia M, Arasi S, Castelli S, et al. A new molecular multiplex IgE assay for the diagnosis of pollen allergy in Mediterranean countries: a validation study. Clin Exp Allergy. 2019;49:341-349.
Buzzulini F, Da Re M, Scala E, et al. Evaluation of a new multiplex IgE assay for allergy diagnosis. Clin Chim Acta. 2019;493:73-78.
Melioli G, Spenser C, Reggiardo G, et al. Allergenius, an expert system for the interpretation of allergen microarray results. World Allergy Organ J. 2014;7(1):15.
Heffler E, Puggioni F, Peveri S, Montagni M, Canonica GW, Melioli G. Extended IgE profile based on an allergen macroarray: a novel tool for precision medicine in allergy diagnosis. World Allergy Organ J. 2018;11(1):7.
Mittermann I, Zidarn M, Silar M, et al. Recombinant allergen-based IgE testing to distinguish bee and wasp allergy. J Allergy Clin Immunol. 2010;125(6):1300-1307.
Sastre J, Landivar ME, Ruiz-García M, Andregnette-Rosigno MV, Mahillo I. How molecular diagnosis can change allergen-specific immunotherapy prescription in a complex pollen area. Allergy. 2012;67(5):709-711.
Moreno C, Justicia JL, Quiralte J, et al. Olive, grass or both? Molecular diagnosis for the allergen immunotherapy selection in polysensitized pollinic patients. Allergy. 2014;69(10):1357-1363.
Popescu FD. Molecular biomarkers for grass pollen immunotherapy. World J Methodol. 2014;4(1):26-45.
Vidal C, Enrique E, Gonzalo A, Moreno C, Tabar AI; Expert Clinical Participants. Diagnosis and allergen immunotherapy treatment of polysensitised patients with respiratory allergy in Spain: an Allergists' Consensus. Clin Transl Allergy. 2014;7(4):36.
Saltabayeva U, Garib V, Morenko M, et al. Greater real-life diagnostic efficacy of allergen molecule based diagnosis for prescription of immunotherapy in an area with multiple pollen exposure. Int Arch Allergy Immunol. 2017;173(2):93-98.
Del-Río Camacho G, Montes Arjona AM, Fernández-Cantalejo Padial J, Rodríguez Catalán J. How molecular diagnosis may modify immunotherapy prescription in multi-sensitized pollen-allergic children. Allergol Immunopathol (Madr). 2018;46(6):552-556.
Savi E, Peveri S, Makri E, Pravettoni V, Incorvaia C. Comparing the ability of molecular diagnosis and CAP-inhibition in identifying the really causative venom in patients with positive tests to Vespula and Polistes species. Clin Mol Allergy. 2016;14:3.
Martínez-Cañavate Burgos A, Torres-Borrego J, Molina Terán AB, et al. Molecular sensitization patterns and influence of molecular diagnosis in immunotherapy prescription in children sensitized to both grass and olive pollen. Pediatr Allergy Immunol. 2018;29(4):369-374.
Peveri S, Pattini S, Costantino MT, et al. Molecular diagnostics improves diagnosis and treatment of respiratory allergy and food allergy with economic optimization and cost saving. Allergol Immunopathol (Madr). 2019;47(1):64-72.
Gupta M, Cox A, Nowak-Węgrzyn A, Wang J. Diagnosis of food allergy. Immunol Allergy Clin North Am. 2018;38(1):39-52.
Volpicella M, Leoni C, Dileo MCG, Ceci LR. Progress in the analysis of food allergens through molecular biology approaches. Cells. 2019;8(9):1073.
Wai CYY, Leung NYH, Leung PSC, Chu KH. Immunotherapy of food allergy: a comprehensive review. Clin Rev Allergy Immunol. 2019;57(1):55-73.
Schröder H, Yman L. Standardization of the RAST inhibition assay. Allergy. 1980;35(3):234-236.
Quercia O, Cova V, Martini M, et al. CAP-Inhibition, molecular diagnostics, and total IgE in the evaluation of Polistes and Vespula double sensitization. Int Arch Allergy Immunol. 2018;177(4):365-369.
Caruso B, Bonadonna P, Bovo C, et al. Wasp venom allergy screening with recombinant allergen testing. Diagnostic performance of rPol d 5 and rVes v 5 for differentiating sensitization to Vespula and Polistes subspecies. Clin Chim Acta. 2016;453:170-173.
Hemmings O, Kwok M, McKendry R, Santos AF. Basophil activation test: old and new applications in allergy. Curr Allergy Asthma Rep. 2018;18(12):77.
Balzer L, Pennino D, Blank S, et al. Basophil activation test using recombinant allergens: highly specific diagnostic method complementing routine tests in wasp venom allergy. PLoS ONE. 2014;9(10):e108619.
Korošec P, Šilar M, Eržen R, et al. Clinical routine utility of basophil activation testing for diagnosis of hymenoptera-allergic patients with emphasis on individuals with negative venom-specific IgE antibodies. Int Arch Allergy Immunol. 2013;161(4):363.
Eržen R, Košnik M, Silar M, Korošec P. Basophil response and the induction of a tolerance in venom immunotherapy: a long-term sting challenge study. Allergy. 2012;67(6):822-830.
Schmid JM, Würtzen PA, Siddhuraj P et al. Basophil Sensitivity Reflects the Long-term Clinical Outcome of Subcutaneous Immunotherapy in Grass Pollen Allergic Patients. Allergy. 2020. http://dx.doi.org/10.1111/all.14264
Wise SK, Lin SY, Toskala E, et al. International consensus statement on allergy and rhinology: allergic rhinitis. Int Forum Allergy Rhinol. 2018;8(2):108-352.
Agusti A, Bel E, Thomas M, et al. Treatable traits: toward precision medicine of chronic airway diseases. Eur Respir J. 2016;47(2):410-419.
Woodruff PG, Agusti A, Roche N, Singh D, Martinez FJ. Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management. Lancet. 2015;385(9979):1789-1798.
Tay TR, Hew M. Comorbid, “treatable traits” in difficult asthma: current evidence and clinical evaluation. Allergy. 2017;101:130.
McDonald VM, Osadnik CR, Gibson PG. Treatable traits in acute exacerbations of chronic airway diseases. Chron Respir Dis. 2019;16:1479973119867954.
Pavord ID, Agusti A. Blood eosinophil count: a biomarker of an important treatable trait in patients with airway disease. Eur Respir J. 2016;47(5):1299-1303.
Simpson AJ, Hekking PP, Shaw DE, et al.; U-BIOPRED Study Group. Treatable traits in the European U-BIOPRED adult asthma cohorts. Allergy. 2019;74(2):406-411.
Fingleton J, Hardy J, Beasley R. Treatable traits of chronic airways disease. Curr Opin Pulm Med. 2018;24(1):24-31.
Bousquet J, Pfaar O, Togias A, et al.; ARIA Working Group. 2019 ARIA Care pathways for allergen immunotherapy. Allergy. 2019;74(11):2087-2102.
Mushra R. Science of omics: perspectives and prospects for human health care. Integr Mol Med. 2016;IMM.1000258. 23(7):327-333.
Abdel-Aziz MI, Neerincx AH, Vijverberg SJ, Kraneveld AD. Maitland-van der Zee AH. Omics for the future in asthma. Semin Immunopathol. 2020;42(1):111-126.
Devillier P, Salvator H, Naline E, Couderc LJ, Gtassin-Delyle S. Metabolomics in the diagnosis and pharmacotherapeutic management of respiratory diseases. Curr Pharm Des. 2917;23(14):2050-2059.
Park CS, Rhim T. Application of proteomics in asthma research. Expert Rev Proteomics. 2011;8(2):221-230.
Martin-Sanchez F, Bellazzi R, Casella V, Dixon W, Lopez-Campos G, Peek N. Progress in characterizing the human exposome: a key step for precision medicine. Yearb Med Inform. 2020;29(1):115-120.
Donovan BM, Bastarache L, Turi KN, Zutter MM, Hartert TV. The current state of omics technologies in the clinical management of asthma and allergic diseases. Ann Allergy Asthma Immunol. 2019;123(6):550-557.
FitzGerald JM, Poureslami I. The need for humanomics in the era of genomics and the challenge of chronic disease management. Chest 2014;146(1):10-12.
Canonica GW, Bagnasco D, Ferrantino G, Ferrando M, Passalacqua G. Update on immunotherapy for the treatment of asthma. Curr Opin Pulm Med. 2016;22(1):18-22.
Durham SR, Yang WH, Pedersen MR, et al. Sublingual immunotherapy with once daily grass allergen tablet: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J. Allergy Clin. Immunol. 2006;117:802-809.
Didier A, Malling HJ, Worm M, et al. Optimal dose, efficacy, and safety of once daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J. Allergy Clin. Immunol. 2007;120:1338-1345.
Wahn U, Tabar A, Kuna P, et al.; SLIT Study Group. Efficacy and safety of 5-grass pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J. Allergy Clin. Immunol. 2009;123:160-166.
Mosbech H, Deckelmann R, de Blay F, et al. Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2014;134(3):568-575.
Bergmann KC, Demoly P, Worm M, et al. Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis. J Allergy Clin Immunol. 2014;133(6):1608-1614.
Batard T, Hrabina A, Bi XZ, et al. Production and proteomic characterization of pharmaceutical-grade Dermatophagoides pteronyssinus and Dermatophagoides farinae extracts for allergy vaccines. Int Arch Allergy Immunol. 2006;140(4):295-305.
Bordas-Le Floch V, Le Mignon M, Bussières L, et al. A combined transcriptome and proteome analysis extends the allergome of house dust mite Dermatophagoides species. PLoS ONE. 2017;12(10):e0185830.
Herland K, Akselsen JP, Skjønsberg OH. Bjermer LHow representative are clinical study patients with asthma or COPD for a larger "real life" population of patients with obstructive lung disease? Respir Med. 2005;99(1):11-19.
Schünemann HJ, Cuello C, Akl EA, et al. Working Group GRADE guidelines: 18. How ROBINS-I and other tools to assess risk of bias in nonrandomized studies should be used to rate the certainty of a body of evidence. J Clin Epidemiol. 2019;111:105-114.
Roche N, Anzueto A, Bosnic Anticevich S, et al.; Respiratory Effectiveness Group Collaborators. The importance of real-life research in respiratory medicine: manifesto of the Respiratory Effectiveness Group: Endorsed by the International Primary Care Respiratory Group and the World Allergy Organization. Eur Respir J. 2019;54(3):1901511.
Sherman RE, Anderson SA, Dal Pan GJ, et al. Real-world evidence - what is it and what can it tell us? N Engl J Med. 2016;375(23):2293-2297.
Wahn U, Bachert C, Heinrich J, Richter H, Zielen S. Real-world benefit of allergen immunotherapy for birch pollen-associated allergic rhinitis and asthma. Allergy. 2018;74(3):594-604.
Zielen S, Devillier P, Heinrich J, Richter H, Wahn U. Sublingual immunotherapy provides long-term relief in allergic rhinitis and reduces the risk of asthma: a retrospective, real-world database analysis. Allergy. 2018;73:165-177.
Hulsen T, Jamuar SS, Moody AR, et al. From big data to precision medicine. Front Med. 2019;6:34.
Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med. 2010;363(4):301-304.
Calderon M, Demoly P, Gert van Wijk R, et al. EAACI: a European declaration on immunotherapy. Designing the future of allergen specific immunotherapy. Clin Transl. Allergy. 2012;2(1):20.
Passalacqua G, Canonica GW. AIT (allergen immunotherapy): a model for the "precision medicine". Clin Mol Allergy. 2015;13:24.
Bachert C, Larché M, Bonini S, et al. Allergen immunotherapy on the way to product-based evaluation - a WAO statement. World Allergy Organ J. 2015;8(1):29.
Pfaar O, Bonini S, Cardona V, et al.; FASIT group. Perspectives in allergen immunotherapy: 2017 and beyond. Allergy. 2018;73(suppl 104):5-23.
Jacobsen L, Wahn U, Bilo MB. Allergen-specific immunotherapy provides immediate, long-term and preventive clinical effects in children and adults: the effects of immunotherapy can be categorised by level of benefit -the centenary of allergen specific subcutaneous immunotherapy. Clin Transl Allergy. 2012;2:8.
Cox LS, Murphey A, Hankin C. The Cost effectiveness of allergen immunotherapy compared with pharmacotherapy for treatment of allergic rhinitis and asthma. Immunol Allergy Clin North Am. 2020;40(1):69-85.
Krishna MT, Knibb RC, Huissoon AP. Is there a role for telemedicine in adult allergy services? Clin Exp Allergy. 2016;46(5):668-677.
Gómez RM, Ansotegui I, Canonica GW. Will precision medicine be available for all patients in the near future? Curr Opin Allergy Clin Immunol. 2019;19(1):75-80.